Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

DE:AYJ0 Stock Latest News

The FlyValneva announces Ixchiq marketing authorization revoked by UK MHRA3w agoVALN

The FlyPfizer, Valneva announce EMA validation for PF-07307405 MAA2M agoPFE VALN
The FlyMidday Fly By: Applied Materials reports Q3 beat, Trump slaps tariffs on drones2M agoW BA
The FlyValneva initiated with a Buy at TD Cowen2M agoVALN
Pre-EarningsVALN Upcoming Earnings Report: What to Expect?2M agoVALN

Valneva Shareholders Back All AGM Resolutions as Board Elects New Chair

Company AnnouncementsValneva Shareholders Back All AGM Resolutions as Board Elects New Chair4M ago6K VALN

Company AnnouncementsValneva Publishes Documentation for June 25, 2026 Annual General Meeting5M ago6K VALN

The FlyValneva files to sell 31.79M ordinary shares for holders5M agoVALN

Company AnnouncementsValneva Ramps Up June 2026 Investor and Medical Conference Presence5M ago6K VALN
Company AnnouncementsValneva Tightens 2026 Guidance and Restructures as Lyme Vaccine Nears Regulatory Filings5M ago6K VALN
Pre-EarningsVALN Earnings Report this Week: Is It a Buy, Ahead of Earnings?5M agoVALN
Company AnnouncementsValneva Sets May 13 Date to Present First-Quarter 2026 Results6M ago6K VALN

Valneva Raises Up to €84 Million via Private Placement Tied to Lyme Vaccine Milestone

Company AnnouncementsValneva Raises Up to €84 Million via Private Placement Tied to Lyme Vaccine Milestone6M ago6K VALN

The FlyValneva downgraded to Sell from Neutral at Goldman Sachs6M agoVALN

The FlyValneva price target lowered to $11 from $13 at Guggenheim6M agoVALN

Company AnnouncementsValneva Showcases Chikungunya Vaccine Progress at World Vaccine Congress in Washington7M ago6K VALN
Company AnnouncementsValneva and Pfizer Report Strong Phase 3 Efficacy for Lyme Disease Vaccine Candidate7M ago6K VALN
The FlyJefferies says Valneva stock weakness presents buying opportunity7M agoVALN
The FlyPfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial7M agoPFE VALN

Valneva Posts 2025 Results, Flags 2026 as Pivotal Year Ahead of Lyme Vaccine Phase 3 Data

Company AnnouncementsValneva Posts 2025 Results, Flags 2026 as Pivotal Year Ahead of Lyme Vaccine Phase 3 Data7M ago6K VALN

The FlyElaris FlexCo secures exclusive global license from Valneva7M agoVALN

Pre-EarningsVALN Earnings Report this Week: Is It a Buy, Ahead of Earnings?7M agoVALN